# Decision Framework Template

**ç”¨é€”**: ç»“æ„åŒ–ä¸´åºŠå†³ç­–è¿‡ç¨‹ï¼Œä»è¯æ®åˆ°æ¨èçš„å®Œæ•´é€»è¾‘é“¾æ¡
**é€‚ç”¨åœºæ™¯**: æ²»ç–—æ–¹æ¡ˆé€‰æ‹©ã€è¯Šæ–­ç­–ç•¥ã€é£é™©è¯„ä¼°

---

## ğŸ¯ Clinical Decision Framework

### Framework Overview

```
[Clinical Question]
        â†“
[Evidence Synthesis] â†’ [Quality Assessment]
        â†“
[Benefit-Risk Analysis] â†’ [Patient Values Integration]
        â†“
[Recommendation] â†’ [Confidence Level] â†’ [Implementation Considerations]
```

---

## 1ï¸âƒ£ Clinical Question Definition

### PICO Framework

| Element | Details | Clinical Relevance |
|---------|---------|-------------------|
| **P** (Population) | [æ‚£è€…ç‰¹å¾] | [ä¸ºä»€ä¹ˆè¿™ä¸ªç¾¤ä½“ç‰¹æ®Šï¼Ÿ] |
| **I** (Intervention) | [å¹²é¢„æªæ–½] | [ä½œç”¨æœºåˆ¶/ç†è®ºåŸºç¡€] |
| **C** (Comparison) | [å¯¹ç…§æªæ–½] | [å½“å‰æ ‡å‡†æ²»ç–—] |
| **O** (Outcomes) | [å…³æ³¨ç»“å±€] | [å¯¹æ‚£è€…æœ€é‡è¦çš„æ˜¯ä»€ä¹ˆï¼Ÿ] |

**Example**:
```
P: 55å²HER2+ HR+ä¹³è…ºç™Œæ‚£è€…ï¼Œä¸€çº¿T/Pæ²»ç–—åè¿›å±•ï¼Œç°æœ‰è„‘è½¬ç§»3ä¸ªç—…ç¶
I: T-DXd 5.4mg/kg IV q3w
C: T-DM1 3.6mg/kg q3w æˆ– Tucatinibç»„åˆæ²»ç–—
O: ä¸»è¦å…³æ³¨PFSï¼ˆå°¤å…¶CNS-PFSï¼‰ã€OSã€å®‰å…¨æ€§ï¼›æ¬¡è¦å…³æ³¨QoL

Clinical Relevance:
- è„‘è½¬ç§»æ˜¯é¢„åä¸è‰¯å› ç´ ï¼Œéœ€è¦CNSç©¿é€æ€§å¥½çš„è¯ç‰©
- æ—¢å¾€å·²æ¥å—T/Pï¼Œéœ€è¦éäº¤å‰è€è¯çš„æ–¹æ¡ˆ
- HR+æç¤ºå¯èƒ½å—ç›Šäºå†…åˆ†æ³Œæ²»ç–—è”åˆï¼ˆæœªæ¥è€ƒè™‘ï¼‰
```

### Key Decision Pointsï¼ˆå…³é”®å†³ç­–ç‚¹ï¼‰

1. **Primary Decision**: [æ ¸å¿ƒæ²»ç–—é€‰æ‹©é—®é¢˜]
2. **Secondary Decisions**:
   - [å‰‚é‡é€‰æ‹©]
   - [è”åˆç”¨è¯]
   - [æ²»ç–—æŒç»­æ—¶é—´]
3. **Contingency Plans**: [å¦‚æœä¸€çº¿æ–¹æ¡ˆå¤±è´¥/ä¸è€å—ï¼Œå¤‡é€‰æ–¹æ¡ˆæ˜¯ä»€ä¹ˆï¼Ÿ]

---

## 2ï¸âƒ£ Evidence Synthesis

### Evidence Base Summary

| Evidence Type | Number of Studies | Total Patients | Quality | Key Findings |
|---------------|------------------|----------------|---------|--------------|
| **RCTs** | n | N | â­â­â­â­â­ | [ä¸»è¦å‘ç°] |
| **Single-arm trials** | n | N | â­â­â­â­â˜† | [ä¸»è¦å‘ç°] |
| **Observational** | n | N | â­â­â­â˜†â˜† | [ä¸»è¦å‘ç°] |
| **Systematic Reviews** | n | N meta | â­â­â­â­â­ | [ä¸»è¦å‘ç°] |

**Example**:
```
RCTs: 1ä¸ª (DESTINY-Breast03, N=524) | â­â­â­â­â­ | T-DXd vs T-DM1: mPFS 28.8m vs 6.8m (HR 0.33)
Single-arm: 2ä¸ª (DESTINY-Breast01/02, N=184+608) | â­â­â­â­â˜† | ORR 60-61%, mPFS 16-17m
Observational: 3ä¸ª (Real-world evidence, N=~500) | â­â­â­â˜†â˜† | ä¸RCTç»“æœä¸€è‡´
```

### GRADE Evidence Profile

| Outcome | â„– of patients (studies) | Certainty | Effect Estimate | Importance |
|---------|------------------------|-----------|-----------------|-----------|
| PFS | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | HR 0.33 (0.26-0.43) | CRITICAL |
| OS | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | HR 0.64 (0.47-0.87) | CRITICAL |
| ORR | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | RR 2.33 (1.95-2.79) | IMPORTANT |
| CNS-PFS | ~100 (subgroup) | âŠ•âŠ•âŠ•âŠ MODERATE | HR 0.25 (0.13-0.50) | CRITICAL |
| Gradeâ‰¥3 AE | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | RR 1.15 (0.92-1.43) | IMPORTANT |

**GRADE Certainty Levels**:
- âŠ•âŠ•âŠ•âŠ• = HIGH: Very confident that the true effect lies close to estimate
- âŠ•âŠ•âŠ•âŠ = MODERATE: Moderately confident (true effect likely close, but could be different)
- âŠ•âŠ•âŠâŠ = LOW: Limited confidence (true effect may differ substantially)
- âŠ•âŠâŠâŠ = VERY LOW: Very little confidence (true effect likely substantially different)

---

## 3ï¸âƒ£ Benefit-Risk Analysis

### Benefit Assessment

| Outcome | Absolute Benefit | NNT | Clinical Significance |
|---------|------------------|-----|----------------------|
| **Primary Efficacy** | | | |
| PFS improvement | +22.0 months | - | æ˜¾è‘—å»¶é•¿ï¼ˆ3.2å€ï¼‰ |
| OS improvement | +9.9 months | ~4 | ä¸´åºŠæœ‰æ„ä¹‰ï¼ˆ>3ä¸ªæœˆï¼‰ |
| CNS-PFS improvement | HR 0.25 | - | è„‘è½¬ç§»æ§åˆ¶ä¼˜å¼‚ |
| **Response** | | | |
| ORR increase | +45.5% (79.7% vs 34.2%) | 2.2 | å¤§å¤šæ•°æ‚£è€…è·ç›Š |
| CR rate | +19.8% (24.5% vs 4.7%) | 5.1 | æ·±åº¦ç¼“è§£ç‡é«˜ |

**NNT (Number Needed to Treat)**: éœ€è¦æ²»ç–—å¤šå°‘æ‚£è€…ï¼Œæ‰èƒ½ä½¿1äººè·ç›Š

### Risk Assessment

| Adverse Event | Incidence Increase | NNH | Management Strategy |
|---------------|-------------------|-----|---------------------|
| **Serious AEs** | | | |
| Gradeâ‰¥3 AEs | +6% (45% vs 39%) | 16.7 | å¯æ¥å—ï¼ˆå¤šä¸ºå¯é€†æ€§è¡€æ¶²å­¦æ¯’æ€§ï¼‰ |
| ILD (any grade) | +13.6% vs baseline | 7.4 | éœ€å¯†åˆ‡ç›‘æµ‹è‚ºéƒ¨ç—‡çŠ¶ |
| ILD (Gradeâ‰¥3) | +2.7% | 37 | ä½å‘ç”Ÿç‡ï¼Œå¯ç®¡ç† |
| **Common AEs** | | | |
| æ¶å¿ƒ | +70% vs 48% | 4.5 | å¯¹ç—‡å¤„ç†ï¼Œå°‘å½±å“æ²»ç–— |
| è„±å‘ | +36% vs 3% | 3.0 | å¯é€†ï¼ŒQoLå½±å“ |

**NNH (Number Needed to Harm)**: éœ€è¦æ²»ç–—å¤šå°‘æ‚£è€…ï¼Œä¼šå¯¼è‡´1äººå‘ç”Ÿä¸è‰¯äº‹ä»¶

### Benefit-Risk Ratio

```
Benefit (PFS gain):     +22.0 months
Risk (Gradeâ‰¥3 AE):      +6% (NNH=16.7)
Serious Risk (ILDâ‰¥3):   +2.7% (NNH=37)

Benefit-Risk Ratio = 22.0m PFS gain / 6% additional Gradeâ‰¥3 AE
                   = æ˜æ˜¾æ­£å‘ï¼ˆbenefitè¿œè¶…riskï¼‰

ç‰¹æ®Šå…³æ³¨: ILDéœ€ç›‘æµ‹ä½†å‘ç”Ÿç‡å¯æ§
```

---

## 4ï¸âƒ£ Patient Values Integration

### Shared Decision-Making Considerations

| Patient Value/Preference | How it affects decision | Example |
|--------------------------|------------------------|---------|
| **æ²»ç–—ç›®æ ‡** | | |
| è¿½æ±‚æœ€å¤§ç”Ÿå­˜è·ç›Š | ä¼˜é€‰ç–—æ•ˆæœ€å¼ºæ–¹æ¡ˆ | â†’ T-DXdï¼ˆPFS/OSæœ€ä¼˜ï¼‰ |
| ä¼˜å…ˆè€ƒè™‘ç”Ÿæ´»è´¨é‡ | å¹³è¡¡ç–—æ•ˆä¸æ¯’æ€§ | â†’ éœ€è¯„ä¼°ILDé£é™©æ¥å—åº¦ |
| æ§åˆ¶ç—‡çŠ¶ï¼ˆå¦‚è„‘è½¬ç§»ï¼‰ | ä¼˜é€‰CNSç©¿é€æ€§å¥½çš„è¯ç‰© | â†’ T-DXdï¼ˆCNS-PFS HR 0.25ï¼‰ |
| **æ²»ç–—ä¾¿åˆ©æ€§** | | |
| å¸Œæœ›å‡å°‘åŒ»é™¢å¾€è¿” | ä¼˜é€‰å£æœè¯ç‰© | â†’ Tucatinibç»„åˆï¼ˆä½†ç–—æ•ˆç•¥å·®ï¼‰ |
| æ¥å—é™è„‰æ²»ç–— | IV q3wå¯æ¥å— | â†’ T-DXdæˆ–T-DM1å‡å¯ |
| **é£é™©æ‰¿å—åº¦** | | |
| ä½é£é™©åå¥½ | ä¼˜å…ˆå®‰å…¨æ€§æ›´å¥½çš„æ–¹æ¡ˆ | â†’ T-DM1ï¼ˆå‰¯ä½œç”¨ç•¥ä½ï¼‰ |
| é«˜é£é™©æ‰¿å—ï¼ˆä¸ºç–—æ•ˆï¼‰ | å¯æ¥å—è¾ƒé«˜æ¯’æ€§ | â†’ T-DXdï¼ˆæ¥å—ILDé£é™©ï¼‰ |
| **ç»æµè€ƒé‡** | | |
| è´¹ç”¨æ•æ„Ÿ | ä¼˜å…ˆè€ƒè™‘æ€§ä»·æ¯” | â†’ è¯„ä¼°è‡ªè´¹vsåŒ»ä¿æŠ¥é”€æƒ…å†µ |
| è´¹ç”¨ä¸æ˜¯ä¸»è¦è€ƒè™‘ | ä¼˜é€‰ç–—æ•ˆæœ€ä¼˜æ–¹æ¡ˆ | â†’ T-DXd |

### Patient-Specific Modifiers

**å¢åŠ T-DXdä¼˜å…ˆçº§çš„å› ç´ ** â¬†ï¸:
- âœ… æœ‰è„‘è½¬ç§»ï¼ˆCNSç–—æ•ˆä¼˜ï¼‰
- âœ… å¹´è½»ã€PSå¥½ï¼ˆèƒ½è€å—æ²»ç–—ï¼‰
- âœ… è¿½æ±‚æœ€å¤§ç–—æ•ˆ
- âœ… æ— è‚ºéƒ¨åŸºç¡€ç–¾ç—…

**é™ä½T-DXdä¼˜å…ˆçº§çš„å› ç´ ** â¬‡ï¸:
- âš ï¸ æ—¢å¾€ILDç—…å²
- âš ï¸ ä¸¥é‡è‚ºéƒ¨åŸºç¡€ç–¾ç—…ï¼ˆè‚ºçº¤ç»´åŒ–ã€æ…¢é˜»è‚ºï¼‰
- âš ï¸ è€å¹´å¤šå¹¶å‘ç—‡ï¼ˆ>75å² + ECOG PSâ‰¥2ï¼‰
- âš ï¸ å¼ºçƒˆåå¥½å£æœæ²»ç–—

---

## 5ï¸âƒ£ Recommendation

### Primary Recommendation

**æ¨èæ–¹æ¡ˆ**: [æ–¹æ¡ˆåç§°]

**æ¨èå¼ºåº¦**:
- ğŸŸ¢ **Strong Recommendation** (å¼ºæ¨è): ç»å¤§å¤šæ•°æ‚£è€…é€‚ç”¨
- ğŸŸ¡ **Conditional Recommendation** (æ¡ä»¶æ¨è): éƒ¨åˆ†æ‚£è€…é€‚ç”¨ï¼Œéœ€ä¸ªä½“åŒ–
- ğŸ”´ **Against** (ä¸æ¨è): ä¸å»ºè®®ä½¿ç”¨

**è¯æ®è´¨é‡**:
- â­â­â­â­â­ High-quality evidence
- â­â­â­â­â˜† Moderate-quality evidence
- â­â­â­â˜†â˜† Low-quality evidence

**Example**:
```
Primary Recommendation: T-DXd 5.4mg/kg IV q3w

Strength: ğŸŸ¢ Strong Recommendation
Evidence: â­â­â­â­â­ High-quality (åŸºäºDESTINY-Breast03 RCT)

Rationale:
1. æ˜¾è‘—PFSè·ç›Šï¼ˆHR 0.33ï¼Œç»å¯¹è·ç›Š+22ä¸ªæœˆï¼‰
2. OSæ”¹å–„ï¼ˆHR 0.64ï¼Œç»å¯¹è·ç›Š+9.9ä¸ªæœˆï¼‰
3. CNSç–—æ•ˆä¼˜å¼‚ï¼ˆHR 0.25ï¼Œé€‚åˆæœ‰è„‘è½¬ç§»çš„æ‚£è€…ï¼‰
4. å®‰å…¨æ€§å¯æ§ï¼ˆGradeâ‰¥3 AE 45% vs 39%ï¼ŒILDå¯ç®¡ç†ï¼‰
5. å·²çº³å…¥å¤šä¸ªæŒ‡å—ä¸€ç±»æ¨èï¼ˆNCCN, ESMOï¼‰
```

### Alternative Recommendations

**å¤‡é€‰æ–¹æ¡ˆ1**: [æ–¹æ¡ˆåç§°]

**é€‚ç”¨åœºæ™¯**: [ä½•æ—¶è€ƒè™‘æ­¤æ–¹æ¡ˆï¼Ÿ]

**Example**:
```
Alternative 1: Tucatinib + Capecitabine + Trastuzumab

é€‚ç”¨åœºæ™¯:
- æ‚£è€…æœ‰ILDé«˜é£é™©å› ç´ æˆ–æ—¢å¾€ILDç—…å²
- å¼ºçƒˆåå¥½å£æœæ²»ç–—
- T-DXdä¸å¯åŠæˆ–ä¸è€å—

Evidence: â­â­â­â­â˜† (HER2CLIMB, Phase II RCT)
Strength: ğŸŸ¡ Conditionalï¼ˆç‰¹å®šåœºæ™¯ä¸‹æ¨èï¼‰
```

**å¤‡é€‰æ–¹æ¡ˆ2**: T-DM1 3.6mg/kg IV q3w

```
é€‚ç”¨åœºæ™¯:
- è€å¹´æ‚£è€…ï¼ˆ>75å²ï¼‰æˆ–PSè¾ƒå·®ï¼ˆECOG 2ï¼‰
- å¤šç§å¹¶å‘ç—‡ï¼Œä¼˜å…ˆè€ƒè™‘å®‰å…¨æ€§
- T-DXdä¸å¯åŠ

Evidence: â­â­â­â­â­ (å¤šä¸ªRCT)
Strength: ğŸŸ¡ Conditionalï¼ˆå®‰å…¨æ€§ä¼˜å…ˆåœºæ™¯ï¼‰
Note: ç–—æ•ˆåŠ£äºT-DXdï¼ˆDESTINY-Breast03ç›´æ¥æ¯”è¾ƒï¼‰
```

### Recommendation for Special Populations

| Subgroup | Recommendation | Modification from standard |
|----------|---------------|---------------------------|
| **è„‘è½¬ç§»æ‚£è€…** | T-DXd (Strong) | æ— éœ€è°ƒæ•´ï¼ŒCNSç–—æ•ˆä¼˜å¼‚ |
| **è€å¹´æ‚£è€…(>75å²)** | T-DXd (Conditional) | éœ€è¯„ä¼°å™¨å®˜åŠŸèƒ½ï¼Œå¯èƒ½éœ€dose reduction |
| **è‚¾åŠŸèƒ½ä¸å…¨** | T-DXd (Conditional) | CrCl>30å¯ç”¨ï¼Œéœ€å¯†åˆ‡ç›‘æµ‹ |
| **è‚åŠŸèƒ½ä¸å…¨** | è°¨æ…ä½¿ç”¨ | è½»åº¦å¯ç”¨ï¼Œä¸­é‡åº¦é¿å… |
| **æ—¢å¾€ILD** | ä¸æ¨èT-DXd | é€‰æ‹©Tucatinibç»„åˆæˆ–T-DM1 |

---

## 6ï¸âƒ£ Implementation Considerations

### Pre-Treatment Checklist

**å¿…é¡»å®Œæˆçš„è¯„ä¼°**:
- [ ] ç¡®è®¤HER2çŠ¶æ€ï¼ˆIHC 3+ æˆ– FISH+ï¼‰
- [ ] åŸºçº¿è‚ºéƒ¨CTï¼ˆæ’é™¤ILDï¼‰
- [ ] è‚è‚¾åŠŸèƒ½è¯„ä¼°
- [ ] LVEFè¯„ä¼°ï¼ˆåŸºçº¿â‰¥50%ï¼‰
- [ ] æ‚£è€…æ•™è‚²ï¼ˆILDç—‡çŠ¶è¯†åˆ«ï¼‰

### Monitoring Plan

| Parameter | Baseline | During Treatment | Post-Treatment |
|-----------|----------|------------------|----------------|
| **ç–—æ•ˆç›‘æµ‹** | | | |
| å½±åƒå­¦è¯„ä¼° | CT/MRI | æ¯2-3ä¸ªå‘¨æœŸ | è¿›å±•å |
| è‚¿ç˜¤æ ‡å¿—ç‰© | CA 15-3, CEA | æ¯å‘¨æœŸ | è¿›å±•å |
| **å®‰å…¨æ€§ç›‘æµ‹** | | | |
| è‚ºéƒ¨ç—‡çŠ¶é—®è¯¢ | - | æ¯æ¬¡å°±è¯Š | - |
| èƒ¸éƒ¨CT | CT | æœ‰ç—‡çŠ¶æ—¶æˆ–æ¯6ä¸ªå‘¨æœŸ | - |
| LVEF | åŸºçº¿ | æ¯3ä¸ªæœˆ | - |
| è‚è‚¾åŠŸèƒ½ | åŸºçº¿ | æ¯å‘¨æœŸ | - |
| è¡€å¸¸è§„ | åŸºçº¿ | æ¯å‘¨æœŸ | - |

### Dose Modification

**T-DXdå‰‚é‡è°ƒæ•´æ ‡å‡†**:

| Toxicity | Grade | Action |
|----------|-------|--------|
| **ILD** | Grade 1 | æš‚åœï¼Œç—‡çŠ¶ç¼“è§£åå¯è€ƒè™‘5.4â†’4.4â†’3.2mg/kg |
| | Grade 2+ | æ°¸ä¹…åœè¯ |
| **ä¸­æ€§ç²’ç»†èƒå‡å°‘** | Grade 3 | æš‚åœè‡³æ¢å¤â‰¥Grade 1ï¼Œå‡é‡ |
| | Grade 4 | æš‚åœï¼Œæ¢å¤åå‡é‡ï¼Œè€ƒè™‘G-CSFæ”¯æŒ |
| **æ¶å¿ƒ/å‘•å** | Grade 3-4 | åŠ å¼ºæ­¢åï¼Œæš‚åœè‡³â‰¤Grade 1 |

**å‰‚é‡æ¢¯åº¦**: 5.4 mg/kg â†’ 4.4 mg/kg â†’ 3.2 mg/kg

### When to Discontinue

**æ²»ç–—ç»ˆæ­¢æŒ‡å¾**:
1. âœ… ç–¾ç—…è¿›å±•ï¼ˆRECIST 1.1æ ‡å‡†ï¼‰
2. âœ… ä¸å¯è€å—çš„æ¯’æ€§ï¼ˆå°¤å…¶ILD Gradeâ‰¥2ï¼‰
3. âœ… æ‚£è€…æ‹’ç»ç»§ç»­
4. âœ… æ­»äº¡

**è„‘è½¬ç§»å±€éƒ¨è¿›å±•å¤„ç†**:
- å¦‚ä»…CNSè¿›å±•ï¼Œå…¨èº«ç–¾ç—…æ§åˆ¶ â†’ è€ƒè™‘å±€éƒ¨æ²»ç–—ï¼ˆSRSï¼‰åç»§ç»­T-DXd
- å¦‚å…¨èº«+CNSè¿›å±• â†’ æ¢çº¿æ²»ç–—

---

## 7ï¸âƒ£ Evidence-to-Recommendation Logic Chain

### Logic Pathway

```
[Question]: HER2+ mBCäºŒçº¿æ²»ç–—é€‰æ‹©

        â†“

[Evidence]: DESTINY-Breast03 RCT
            - T-DXd vs T-DM1
            - mPFS: 28.8m vs 6.8m (HR 0.33, p<0.001)
            - mOS: æœªè¾¾åˆ° vs 34.2m (HR 0.64, p=0.001)
            - CNS-PFS: HR 0.25

        â†“

[Quality]: â­â­â­â­â­ High
            - RCT, large sample (N=524)
            - Low risk of bias
            - Consistent results across subgroups

        â†“

[Benefit]: +22.0m PFS, +9.9m OS, ORR +45.5%
            ä¸´åºŠæ„ä¹‰æ˜¾è‘—ï¼ˆ>3å€PFSå»¶é•¿ï¼‰

        â†“

[Risk]:     Gradeâ‰¥3 AE +6% (NNH=16.7)
            ILDé£é™©+13.6% (ä½†Gradeâ‰¥3ä»…2.7%)
            å¯ç®¡ç†ï¼Œbenefitè¿œè¶…risk

        â†“

[Patient Values]:
            - å¤§å¤šæ•°æ‚£è€…ä¼˜å…ˆè€ƒè™‘ç–—æ•ˆï¼ˆå°¤å…¶æœ‰è„‘è½¬ç§»ï¼‰
            - ILDé£é™©å¯é€šè¿‡ç›‘æµ‹ç®¡ç†
            - é™è„‰ç»™è¯q3wæ¥å—åº¦é«˜

        â†“

[Recommendation]: ğŸŸ¢ Strong Recommendation for T-DXd
                  è¯æ®å……åˆ†ã€è·ç›Šæ˜ç¡®ã€é£é™©å¯æ§

        â†“

[Implementation]:
            - åŸºçº¿è‚ºCTç­›æŸ¥
            - æ²»ç–—ä¸­å¯†åˆ‡ç›‘æµ‹ILD
            - æ‚£è€…æ•™è‚²ç—‡çŠ¶è¯†åˆ«
```

---

## 8ï¸âƒ£ Uncertainty & Future Directions

### Remaining Uncertainties

| Question | Current Evidence | What's Needed |
|----------|------------------|---------------|
| **æœ€ä½³æ²»ç–—çº¿æ•°** | äºŒçº¿æ•°æ®æœ€å……åˆ† | ä¸€çº¿vs T/Pçš„å¤´å¯¹å¤´RCTï¼ˆDESTINY-Breast09è¿›è¡Œä¸­ï¼‰ |
| **æœ€ä½³æ²»ç–—æŒç»­æ—¶é—´** | æŒç»­è‡³è¿›å±•ä¸ºæ ‡å‡† | å›ºå®šç–—ç¨‹ vs æŒç»­æ²»ç–—çš„ç ”ç©¶ |
| **ä¸å…ç–«æ²»ç–—è”åˆ** | ç¼ºä¹æ•°æ® | T-DXd + PD-1æŠ‘åˆ¶å‰‚çš„IIæœŸè¯•éªŒ |
| **ç”Ÿç‰©æ ‡å¿—ç‰©é¢„æµ‹** | HER2 IHC/FISHä¸ºå‡† | HER2ä½è¡¨è¾¾ã€PIK3CAçªå˜ç­‰çš„é¢„æµ‹ä»·å€¼ |

### Ongoing Trials

| Trial ID | Design | Question | Expected Results |
|----------|--------|----------|------------------|
| NCT03734029 | Phase III | T-DXd vs investigator's choice (1L) | 2026 |
| NCT04538742 | Phase III | T-DXd vs T-DM1 (adjuvant) | 2027 |
| NCT04622319 | Phase Ib/II | T-DXd + pembrolizumab | 2025 |

**å¦‚ä½•æ›´æ–°æ¨è**:
- DESTINY-Breast09ç»“æœå…¬å¸ƒ â†’ å¯èƒ½å°†T-DXdæ¨èæå‰è‡³ä¸€çº¿
- è¾…åŠ©æ²»ç–—è¯•éªŒé˜³æ€§ â†’ æ‰©å±•è‡³æ—©æœŸä¹³è…ºç™Œ
- è”åˆå…ç–«æ²»ç–—æ•°æ®æˆç†Ÿ â†’ å¯èƒ½æ”¹å˜æ²»ç–—ç­–ç•¥

---

## ğŸ¯ Decision Summary (One-Pager)

### For Quick Reference

**Clinical Question**: HER2+ä¹³è…ºç™ŒäºŒçº¿æ²»ç–—é€‰æ‹©

**Best Option**: T-DXd 5.4mg/kg IV q3w

**Evidence**: â­â­â­â­â­ RCT (DESTINY-Breast03)

**Benefit**: mPFS 28.8m vs 6.8m (HR 0.33), mOS æœªè¾¾åˆ° vs 34.2m (HR 0.64)

**Risk**: Gradeâ‰¥3 AE 45%, ILD 13.6% (Gradeâ‰¥3: 2.7%)

**Recommendation Strength**: ğŸŸ¢ Strong

**Who benefits most**: æœ‰è„‘è½¬ç§»ã€å¹´è½»ã€PSå¥½ã€è¿½æ±‚æœ€å¤§ç–—æ•ˆçš„æ‚£è€…

**Who should avoid**: æ—¢å¾€ILDã€ä¸¥é‡è‚ºç—…ã€è€å¹´å¤šå¹¶å‘ç—‡

**Alternatives**: Tucatinibç»„åˆï¼ˆå£æœåå¥½/ILDé«˜é£é™©ï¼‰ã€T-DM1ï¼ˆå®‰å…¨æ€§ä¼˜å…ˆï¼‰

**Key Monitoring**: è‚ºéƒ¨ç—‡çŠ¶ã€æ¯æ¬¡é—®è¯Šè¯¢é—®å‘¼å¸å›°éš¾/å’³å—½

---

## ğŸ“š References

1. CortÃ©s J, et al. N Engl J Med. 2022;386(12):1143-1154. (DESTINY-Breast03)
2. Modi S, et al. N Engl J Med. 2020;382(7):610-621. (DESTINY-Breast01)
3. NCCN Guidelines: Breast Cancer v5.2024
4. ESMO Clinical Practice Guidelines: Breast Cancer 2023

---

*Template Version: 1.0*
*Last Updated: 2025-12-07*
*Part of: Medical Research Analyst Skill - LiYe OS*
